Clinical trials: Pancreatic Cancer Stage II
Pancreatic Cancer
Gemcitabine and Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00006117
- Testing
- gemcitabine hydrochloride, oxaliplatin
- Where
- 10 sites in Belgium, France
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Metastatic Malignant Neoplasm in the Liver, Pancreatic Neuroendocrine Tumor
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
This phase II trial studies the effect of capecitabine and temozolomide after surgery in treating patients with high-risk well-differentiated pancreatic neuroendocrine tumors.
- Conditions
- Metastatic Malignant Neoplasm in the Liver, Pancreatic Neuroendocrine Tumor, Stage I Pancreatic Neuroendocrine Tumor AJCC v8, Stage II Pancreatic Neuroendocrine Tumor AJCC v8
- Trial name
- NCT05040360
- Testing
- Capecitabine, Temozolomide
- Where
- 448 sites in United States, Mexico and 1 more
- Volunteers
- 141 people
- Sponsor
- SWOG Cancer Research Network
Gastrointestinal Carcinoid Tumor, Islet Cell Carcinoma
Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors
RATIONALE: Vatalanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by stopping blood flow to the tumor. Octreotide may help control symptoms, such as diarrhea, caused by the tumor.
- Trial name
- NCT00227773
- Testing
- octreotide acetate, vatalanib, anti-cytokine therapy
- Sponsor
- Eastern Cooperative Oncology Group
Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
This randomized phase I/II trial studies gemcitabine hydrochloride and vismodegib to see how well they work compared with gemcitabine hydrochloride alone in treating patients with recurrent or metastatic pancreatic cancer.
- Conditions
- Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma, Stage IV Pancreatic Cancer AJCC v6 and v7
- Trial name
- NCT01064622
- Testing
- Gemcitabine Hydrochloride, Vismodegib
- Where
- 25 sites in United States
- Volunteers
- 118 people
- Sponsor
- National Cancer Institute (NCI)
Solid Tumor, Breast Tumor
Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors
The purpose of this study is to further evaluate the efficacy and safety of niraparib in patients with locally advanced or metastatic solid tumors and a pathogenic or likely pathogenic tumor PALB2 (tPALB2) mutation.
- Conditions
- Solid Tumor, Breast Tumor, Colon Tumor, Malignant, Lung Tumor
- Trial name
- PAVO (NCT05169437)
- Testing
- Niraparib
- Where
- 80 sites in United States
- Volunteers
- 22 people
- Sponsor
- Tempus AI
Gastrinoma, Glucagonoma
Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors
This randomized phase II trial studies how well giving temozolomide with or without capecitabine works in treating patients with advanced pancreatic neuroendocrine tumors.
- Conditions
- Gastrinoma, Glucagonoma, Insulinoma, Islet Cell Carcinoma
- Trial name
- NCT01824875
- Testing
- temozolomide, capecitabine
- Where
- 323 sites in United States
- Volunteers
- 144 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Pancreatic Cancer
Irinotecan, Gemcitabine and Radiation Therapy for Pancreatic Cancer
The study hypothesis is that chemoradiation based on 2 drugs will improve local control and long-term survival in patients with locally advanced pancreatic cancer.
- Trial name
- NCT00192712
- Testing
- irinotecan, gemcitabine
- Where
- Israel
- Volunteers
- 20 people
- Sponsor
- Rambam Health Care Campus
Pancreatic Cancer
Opioid Growth Factor in Treating Patients With Advanced Pancreatic Cancer That Cannot Be Removed By Surgery
RATIONALE: Opioid growth factor may stop the growth of pancreatic cancer by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well opioid growth factor works in treating patients with advanced…
- Trial name
- OGF (NCT00109941)
- Testing
- opioid growth factor, metenkephalin, OGF-opioid growth factor
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Milton S. Hershey Medical Center
Advance Solid Tumors, Colon and Rectal Cancer
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations
This is a Phase 1 and Phase 2 study to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of INV-8989 in patients with advanced solid tumors harboring KRAS G12D mutations.
- Conditions
- Advance Solid Tumors, Colon and Rectal Cancer, Non - Small Cell Lung Cancer NSCLC, Pancreatic Adenocarcinoma Advanced or Metastatic
- Trial name
- NCT07610798
- Testing
- INV-8989
- Where
- China
- Volunteers
- 178 people
- Sponsor
- Shenzhen Ionova Life Sciences Co., Ltd.
Pancreatic Cancer
Phase I/II Intratumoral DC Immunotherapy With Gemcitabine & XRT in Unresectable Pancreatic Cancer
To determine the safety, feasibility and appropriate dendritic cell dose to vaccinate patients with pancreas cancer
- Trial name
- NCT00547144
- Testing
- Gemcitabine, Dendritic Cell Immunotherapy
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- George Albert Fisher
Metastatic Pancreatic Cancer
Efficacy of ABI-007 Plus Gemcitabine or sLV5FU2 as First-line Therapy in Patients With Metastatic Pancreatic Cancer
To evaluate the combination of ABI-007 with gemcitabine or with LV5FU2.
- Trial name
- AFUGEM (NCT01964534)
- Testing
- ABI-007, Gemcitabine, simplified LV5FU2
- Where
- 15 sites in France
- Volunteers
- 114 people
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Extrahepatic Bile Duct Cancer, Gallbladder Cancer
Radiation Therapy in Treating Patients With Bile Duct, Gallbladder, or Pancreatic Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Motexafin gadolinium may increase the effectiveness of radiation therapy by making tumor cells more sensitive to treatment.
- Conditions
- Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Pancreatic Cancer
- Trial name
- NCT00003411
- Testing
- motexafin gadolinium, radiation therapy
- Where
- 3 sites in United States
- Sponsor
- University of Pittsburgh
Pancreatic Cancer
Stereotactic Body Radiation Therapy Followed by NALIRIFOX vs NALIRIFOX for Borderline Resectable Pancreatic Cancer
This multicentric open-label trial will compare the efficacy and safety of stereotactic body radiation therapy (SBRT) followed by NALIRIFOX (5-fluorouracil, leucovorin, irinotecan liposome injection and oxaliplatin) vs NALIRIFOX…
- Trial name
- NCT06259058
- Testing
- Irinotecan liposome injection, Oxaliplatin, 5-Fluorouracil
- Volunteers
- 96 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Pancreatic Cancer
Safety/Efficacy Study of Rexin-G to Treat Pancreatic Cancer
The goal of the adaptive trial design is to determine the over-all safety of escalating doses of Rexin-G and to determine the optimal dosing regimen for Rexin-G that would document the significant clinical benefits required to…
- Trial name
- NCT00504998
- Testing
- Rexin-G
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- Epeius Biotechnologies
Intraductal Papillary Mucinous Neoplasm of the Pancreas, Recurrent Pancreatic Cancer
Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving erlotinib hydrochloride before surgery may make the tumor smaller and reduce the amount of normal tissue…
- Conditions
- Intraductal Papillary Mucinous Neoplasm of the Pancreas, Recurrent Pancreatic Cancer, Stage IA Pancreatic Cancer, Stage IB Pancreatic Cancer
- Trial name
- NCT00482625
- Testing
- erlotinib hydrochloride, conventional surgery, immunohistochemistry staining method
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- National Cancer Institute (NCI)
Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer
UCN-01 and Gemcitabine in Treating Patients With Unresectable or Metastatic Pancreatic Cancer
Phase I trial to study the effectiveness of combining UCN-01 with gemcitabine in treating patients who have unresectable or metastatic pancreatic cancer.
- Conditions
- Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage II Pancreatic Cancer, Stage III Pancreatic Cancer
- Trial name
- NCT00039403
- Testing
- 7-hydroxystaurosporine, gemcitabine hydrochloride, pharmacological study
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma
Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
This randomized phase II trial studies how well veliparib together with gemcitabine hydrochloride and cisplatin works compared to gemcitabine hydrochloride and cisplatin alone in treating patients with pancreatic cancer that has…
- Conditions
- Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
- Trial name
- NCT01585805
- Testing
- Biopsy Procedure, Biospecimen Collection, Cisplatin
- Where
- 12 sites in United States, Canada and 1 more
- Volunteers
- 83 people
- Sponsor
- National Cancer Institute (NCI)
Pancreatic Cancer
A Phase I-II Study of PAXG in Stage III-IV Pancreatic Adenocarcinoma
Four-drug combo yielded a statistically significant improvement in progression-free survival and overall survival compared to gemcitabine in patients with advanced pancreatic adenocarcinoma.
- Trial name
- PACT-19 (NCT01730222)
- Testing
- cisplatin, capecitabine, gemcitabine
- Where
- Italy
- Volunteers
- 137 people
- Sponsor
- IRCCS San Raffaele
Pancreatic Cancer
Panitumumab, Chemotherapy, and External-Beam Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot be Removed by Surgery
RATIONALE: Monoclonal antibodies, such as panitumumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00601627
- Testing
- panitumumab, capecitabine, fluorouracil
- Where
- 281 sites in United States
- Volunteers
- 52 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Phase II, Open-label, Parallel 2-arm, Multi-center
A Phase II Randomized Study of Gemcitabine and Nab-paclitaxel in Combination With S- 1/LV (GASL) or Oxaliplatin (GAP) as First-line Treatment for Metastatic Pancreatic Cancer
Gemcitabine and nab-paclitaxel are one standard of care for metastatic pancreatic adenocarcinoma (mPDAC) but the progression free survival (PFS) of the regimen is only 5.5 months.
- Trial name
- NCT05026905
- Testing
- Gemcitabine 1000 mg, Nab paclitaxel, S1
- Where
- 4 sites in Taiwan
- Volunteers
- 66 people
- Sponsor
- National Health Research Institutes, Taiwan